Importer of Controlled Substances Registration, 55639 [2017-25284]
Download as PDF
<![CDATA[
55639
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
While Congress also amended section
‘‘824(a) to add to the current bases for
denial, revocation, or suspension of
registration a finding that registration
would be inconsistent with the public
interest on the grounds specified in
[section] 823, which will include
consideration of the new factors added
by’’ the amendment, id. at 266–67,
Congress did not otherwise alter the text
of section 824(a), which makes clear
that the various paragraphs of this
provision are findings, each of which
provides an independent and adequate
ground to support agency action against
a registration, and not discretionary
factors to be considered by the Agency.
Indeed, Respondent points to nothing in
the language of section 824 or the CSA’s
legislative history to support his
position, which would fundamentally
alter the scope of the Agency’s authority
under section 824.
I therefore reject Respondent’s
contentions. Based on the ALJ’s finding
that Respondent is not currently
authorized to dispense controlled
substances in Mississippi, the State in
which he holds the DEA registration at
issue in this proceeding, I will adopt the
ALJ’s recommended order that I revoke
his registration.
DEPARTMENT OF JUSTICE
Order
ACTION:
Pursuant to the authority vested in me
by 21 U.S.C. 824(a), as well as 28 CFR
0.100(b), I order that DEA Certificate of
Registration No. AF2451261 issued to
Arnold E. Feldman, M.D., be, and it
hereby is, revoked. This Order is
effective immediately.9
SUMMARY:
Dated: November 13, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017–25287 Filed 11–21–17; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration as importers of various
classes of schedule I or II controlled
substances.
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
Company
FR Docket
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Almac Clinical Services Incorp (ACSI) ........................................................................................................
Stepan Company .........................................................................................................................................
Fresenius Kabi USA, LLC ...........................................................................................................................
Cambrex Charles City .................................................................................................................................
Spex Certiprep Group, LLC .........................................................................................................................
Akorn, Inc ....................................................................................................................................................
Fisher Clinical Services, Inc ........................................................................................................................
Siegfried USA, LLC .....................................................................................................................................
Mylan Pharmaceuticals, Inc ........................................................................................................................
KVK-Tech, Inc .............................................................................................................................................
Cerilliant Corporation ...................................................................................................................................
Unither Manufacturing LLC .........................................................................................................................
Mylan Pharmaceuticals, Inc ........................................................................................................................
Catalent Centers, LLC .................................................................................................................................
Specgx LLC .................................................................................................................................................
Sharp Clinical Services, Inc ........................................................................................................................
Cody Laboratories, Inc ................................................................................................................................
Bellwyck Clinical Services ...........................................................................................................................
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the
registration of the listed registrants to
import the applicable basic classes of
schedule I or II controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated each company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
9 While the Mississippi Board Order was based on
the Louisiana Board’s Order, as noted in the former
Acting Administrator’s Decision and Order which
revoked Respondent’s Louisiana registration, the
Louisiana Board found proved the sixth charge of
the Administrative Complaint in that proceeding, in
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
Notice of registration.
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substances to
the above listed persons.
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
37114
41054
41053
41055
42120
42117
42121
42117
42120
42119
43404
43571
43572
43569
43571
43572
45612
45613
Published
August 8, 2017.
August 29, 2017.
August 29, 2017.
August 29, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 15, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 29, 2017.
September 29, 2017.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Linda M. Shuck, D.O.; Decision and
Order
BILLING CODE 4410–09–P
On July 25, 2017, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration, issued an Order to
Show Cause to Linda M. Shuck
(Registrant), of Dobson, North Carolina.
The Show Cause Order proposed the
revocation of Registrant’s Certificate of
Registration, on the ground that she
that Respondent violated state law by
‘‘[p]rescribing, dispensing, or administering legally
controlled substances or any dependency-inducing
medication without legitimate medical justification
thereof or in other than a legal or legitimate
manner.’’ See 82 FR at 39618 n.8 (2017); see also
Mot. for Summ. Disp., Appendix B, at 22, 24
(Louisiana Board Order at 12, 14). For the same
reasons as those cited by the former Acting
Administrator, I find that the public interest
necessitates that this Order be effective
immediately. See also 21 CFR 1316.67.
Dated: November 16, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–25284 Filed 11–21–17; 8:45 am]
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
E:\FR\FM\22NON1.SGM
22NON1
]]>Agencies
[Federal Register Volume 82, Number 224 (Wednesday, November 22, 2017)]
[Notices]
[Page 55639]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25284]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Registration
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Registrants listed below have applied for and been granted
registration by the Drug Enforcement Administration as importers of
various classes of schedule I or II controlled substances.
SUPPLEMENTARY INFORMATION: The companies listed below applied to be
registered as importers of various basic classes of controlled
substances. Information on previously published notices is listed in
the table below. No comments or objections were submitted and no
requests for hearing were submitted for these notices.
----------------------------------------------------------------------------------------------------------------
Company FR Docket Published
----------------------------------------------------------------------------------------------------------------
Almac Clinical Services Incorp (ACSI)... 82 FR 37114 August 8, 2017.
Stepan Company.......................... 82 FR 41054 August 29, 2017.
Fresenius Kabi USA, LLC................. 82 FR 41053 August 29, 2017.
Cambrex Charles City.................... 82 FR 41055 August 29, 2017.
Spex Certiprep Group, LLC............... 82 FR 42120 September 6, 2017.
Akorn, Inc.............................. 82 FR 42117 September 6, 2017.
Fisher Clinical Services, Inc........... 82 FR 42121 September 6, 2017.
Siegfried USA, LLC...................... 82 FR 42117 September 6, 2017.
Mylan Pharmaceuticals, Inc.............. 82 FR 42120 September 6, 2017.
KVK-Tech, Inc........................... 82 FR 42119 September 6, 2017.
Cerilliant Corporation.................. 82 FR 43404 September 15, 2017.
Unither Manufacturing LLC............... 82 FR 43571 September 18, 2017.
Mylan Pharmaceuticals, Inc.............. 82 FR 43572 September 18, 2017.
Catalent Centers, LLC................... 82 FR 43569 September 18, 2017.
Specgx LLC.............................. 82 FR 43571 September 18, 2017.
Sharp Clinical Services, Inc............ 82 FR 43572 September 18, 2017.
Cody Laboratories, Inc.................. 82 FR 45612 September 29, 2017.
Bellwyck Clinical Services.............. 82 FR 45613 September 29, 2017.
----------------------------------------------------------------------------------------------------------------
The Drug Enforcement Administration (DEA) has considered the
factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the
registration of the listed registrants to import the applicable basic
classes of schedule I or II controlled substances is consistent with
the public interest and with United States obligations under
international treaties, conventions, or protocols in effect on May 1,
1971. The DEA investigated each company's maintenance of effective
controls against diversion by inspecting and testing each company's
physical security systems, verifying each company's compliance with
state and local laws, and reviewing each company's background and
history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the DEA has granted a registration as
an importer for schedule I or II controlled substances to the above
listed persons.
Dated: November 16, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-25284 Filed 11-21-17; 8:45 am]
BILLING CODE 4410-09-P
